You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

138 Results
Regimen
Cancer Type:
Gynecologic, 
Cervix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023
Guidelines and Advice
Status: Current
ID: GL-END 3-25
Nov 2023
Guidelines and Advice
Status: Current
ID: PET 2023-1
Nov 2023
Guidelines and Advice
Status: Current
ID: GL 16-3
Version: 3
Mar 2022
Guidelines and Advice
Status: Current
ID: GL END 9-10
Version: 2
Aug 2022
Guidelines and Advice
Status: Current
ID: ES 15-5
Version: 3
Nov 2023

Pages